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Abstract 
Periodontitis, a disease involving supportive structures of the teeth prevails in 
all groups, ethnicities, races and both genders. The relationship between 
bacterial plaque and the development of periodontal disease and caries is well 
established. Antibacterial  agents have been used effectively in the 
management of periodontal infection. The effectiveness of mechanical 
debridement of plaque and repeated topical and systemic administration of 
antibacterial agents are limited due to the lack of accessibility to 
periodontopathic organisms in the periodontal pocket. Systemic 
administration of drugs leads to therapeutic concentrations at the site of 
infection, but for short periods of time, forcing repeated dosing for longer 
periods. Local delivery of antimicrobials has been investigated for the 
possibility of overcoming the limitations of conventional therapy. The use of 
sustained release formulations to deliver antibacterials to the site of infection 
(periodontal pocket) has recently gained interest. These products provide a 
long-term, effective treatment at the site of infection at much smaller doses. 
Biodegradable polymers are extensively employed in periodontal drug 
delivery devices because of their abundant source, lack of toxicity, and high 
tissue compatibility. A major advantage of natural polymers is that they do 
not affect periodontal tissue regeneration. Amongst various natural polymers, 
chitosan, a deacetylated product of chitin is widely used in drug delivery 
devices. Since it exhibits favourable biological properties such as non-
toxicity, biocompatibility, biodegradability and wound healing traits, it has 
attracted great attention in the pharmaceutical and biomedical fields. The 
conventional treatment consists of tooth surface mechanical cleaning and root 
planning, associated or not to the systemic use of high concentrations of 
antibiotics, but with reduced effectiveness, and adverse effects. The patient 
compliance to the therapeutic is committed too. In the last decades, the 
treatment has been optimized for the use of drug delivery systems to the 
periodontal pocket, with the advantage of delivering the drug in the specific 
site, sustaining and/or controlling the drug concentration. Recently, the use of 
new drug delivery systems has been receiving great interest. This review 
approaches the main delivery systems for the administration of drugs to the 
periodontal pocket, their usefulness, as well as the advancement of these 
systems effectiveness in the periodontal therapy. 
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Introduction  
Gingivitis and periodontitis are the two major forms 
of inflammatory diseases affecting the 
periodontium. Gingivitis is inflammation of the 
gingiva that does not result in clinical attachment 
loss. Periodontitis is inflammation of the gingival 
and the adjacent attachment apparatus and is 
characterized by loss of connective tissue 
attachment and alveolar bone. Each of these 
diseases may be subclassified based upon etiology, 
clinical presentation, or associated complicating 
factors. Gingivitis is a reversible disease. Therapy is 
aimed primarily at reduction of etiologic factors to 
reduce or eliminate inflammation, thereby allowing 
gingival tissues to heal. Appropriate supportive 
periodontal maintenance that includes personal and 
professional care is important in preventing re-
initiation of inflammation. Therapeutic approaches 
for periodontitis fall into two major categories: 1) 
anti-infective treatment, which is designed to halt 
the progression of periodontal attachment loss by 
removing etiologic factors; and 2) regenerative 
therapy, which includes anti-infective treatment and 
is intended to restore structures destroyed by 
disease. Essential to both treatment approaches is 
the inclusion of periodontal maintenance 
procedures. Inflammation of the periodontium may 
result from many causes (eg, bacteria, trauma). 
However, most forms of gingivitis and periodontitis 
result from the accumulation of tooth-adherent 
microorganisms. Prominent risk factors for 
development of chronic periodontitis include the 
presence of specific subgingival bacteria, tobacco 
use, diabetes Furthermore, there is evidence that 
other factors can contribute to periodontal disease 
pathogenesis: environmental, genetic, and systemic 
(eg, diabetes). Periodontitis is a chronic bacterial 
infection that affects the gums and bones supporting 
teeth, untreated gingivitis can advance to 
periodontitis [1]. Gingivitis is often caused by 
inadequate oral hygiene. Periodontal disease can 
affect one tooth or many teeth. It begins when the 
bacteria in plaque as the disease progresses, the 
pockets deepen and more gum tissues and bone are 
destroyed. Often this destructive process has very 
mild symptoms. Eventually teeth become loosened 
and may have to be removed. Periodontal pocket 
provides an ideal environment for the growth of 
anaerobic pathogenic bacteria such as actinobacillus 
Actinomycetemcomitans, Bacteroides gingivalis, 
Bacteroides melaninogenicus subspecies 
intermedius, Porphyromonas gingivalis and 
Provetella intermedia [2].  
 
Various approaches to treat periodentitis  
Gingivitis can usually be treated simply. 
Plaque and tartar are removed from teeth; the 
inflamed tissues around a tooth usually heal quickly 
and completely More serious cases of periodontitis 
cannot be treated by routine dental procedures 
dental surgery may be necessary to remove plaque, 
tartar, and infected gums tissue. Surgical access to 
facilitate mechanical instrumentation of the roots 
has been utilized to treat chronic periodontitis for 
decades [3]. A surgical approach to the treatment of 
periodontitis is utilized in an attempt, provide better 
access for removal of etiologic factors, reduce deep 
probing depth and regenerate or reconstruct lost 
periodontal tissues.  
 
Chronic Periodontitis 
Appropriate therapy for patients with periodontitis 
varies considerably with the extent and pattern of 
attachment loss, local anatomical variations, type of 
periodontal disease, and therapeutic objectives. 
Periodontitis destroys the attachment apparatus of 
teeth resulting in periodontal pocket formation and 
alteration of normal osseous anatomy. The primary 
objectives of therapy for patients with chronic 
periodontitis are to halt disease progression and to 
resolve inflammation [4]. Therapy at a diseased site 
is aimed at reducing etiologic factors below the 
threshold capable of producing breakdown, thereby 
allowing repair of the affected region. Regeneration 
of lost periodontal structures can be enhanced by 
specific procedures. However, many variables 
responsible for complete regeneration of the 
periodontium are unknown and research is ongoing 
in this area. 
 
Local Delivery 
Local application into periodontal pocket could be 
very advantageous, both in terms of raising drug 
concentration directly in the action site, and in 
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preventing systemic side effects such as 
gastrointestinal complaints, depression, and 
tachycardia. Controlled delivery of 
chemotherapeutic agents within periodontal pockets 
can alter the pathogenic flora and improve clinical 
signs of periodontitis. Local drug delivery systems 
provide several benefits; the drug can be delivered 
to the site of disease activity at a bactericidal 
concentration and it can facilitate prolonged drug 
delivery [5]. The FDA has approved the use of an 
ethylene vinyl acetate fiber that contains 
tetracycline, a gelatin chip that contains 
chlorhexidine and a minocycline polymer 
formulation as adjuncts to scaling and root planing. 
The FDA has also approved doxycycline hyclate in 
a bioabsorbable polymer gel as a stand-alone 
therapy for the reduction of probing depths, 
bleeding upon probing, and gain of clinical 
attachment [6]. Local delivery systems have 
potential limitations and benefits. If used as a 
monotherapy, problems associated with local 
delivery can include allergic reaction, possible 
inability to disrupt biofilms, and failure to remove 
calculus. The benefits include the ease of 
application, selectively targeting a limited number 
of diseased sites that were unresponsive to 
conventional therapy, and possibly enhanced 
treatment results at specific locations. Local 
delivery modalities have shown beneficial clinical 
improvements with regard to probing depth 
reduction and gain in clinical attachment. 
Furthermore, there are limited data to suggest that 
local delivery of antibiotics may also be beneficial 
in preventing recurrent attachment loss in the 
absence of maintenance therapy. Utilization of 
antibiotics at an individual site will depend on the 
discretion of the treating therapist after consultation 
with the patient. The greatest potential of local 
delivery devices may be to enhance therapy at sites 
that do not respond to conventional treatment. 
Ultimately, the results of local drug delivery must 
be evaluated with regard to the magnitude of 
improvement that can be attained relative to disease 
severity.  Conventional drug formulations for the 
mouth, such as toothpaste and mouthwash, have 
very low penetration into periodontal pocket Films 
appear to be a suitable dosage form to deliver drugs 
into periodontal pocket, because the anatomic 
construction of the pocket allows for relatively easy 
insertion of such a delivery device. Moreover, the 
use of biodegradable polymers can increase patient 
compliance, as the inserted film does not need to be 
removed.   Commercially speaking, periodontal 
delivery systems are available on the US market, 
such as PerioChip®, consisting of across-linked 
gelatin matrix capable to maintain chlorhexidine 
concentration for up to 7 days Existing approaches 
for local drug delivery in periodontal pocket are 
often unsatisfactory due to their rapid drug release 
or poor biodegradability of polymeric carrier [7]. 
Adverse drug reactions are a greater concern and 
more likely to occur if drugs are distributed via 
systemic route. An ideal formulation should exhibit 
ease of delivery, good retention at application site, 
and controlled release of drug. Treatment with 
antibiotic may be necessary if infection is present 
introduction of locally delivered antibiotics 
especially for the treatment of localized disease [8]. 
Systemic antibiotic therapy should be reserved for 
juvenile periodontitis, patients with medical 
problems requiring antibiotic coverage, patients 
with severe/acute periodontal infections. 
Metronidazole plus amoxicillin, or ciprofloxacin 
have been used successfully in the treatment of 
advanced Actinomycetemcomitans [9]. Most if the 
dentist (71%) prescribed a combination of 
amoxicillin plus metronidazole, the prescription 
frequency and choice of combination of 
metronidazole and broad spectrum penicillin shows 
the colonization resistance by means of antibiotics 
and worldwide concern about the usage of 
antibiotics. The treatment of periodontitis usually 
involves a systemic regimen with antibiotics to alter 
the presumably pathogenic flora. Furthermore, 
some tetracyclines, by inhibiting collagenase, seem 
to diminish bone destruction. Another approach is 
to surgically eliminate the pocket and recontour the 
bone to encourage alveolar bone growth. Recently, 
some authors investigated the potential application 
of ipriflavone, a synthetic flavonoid derivative, on 
the healing process of experimentally injured rat 
perialveolar bone.This compound is usually 
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employed in the treatment of post-menopausal and 
senile osteoporosis by oral administration. 
Disadvantages of systemic antibiotic therapy relate 
to the fact that the drug is dissolved by dispersal 
over whole body and a small portion of total does 
actually reaches the subgingival microflora in 
periodontal pocket.s 
 
Drug delivery systems for treating  periodontits 
Various drug delivery system for treating 
periodontits – Fibers, Film, Injectable systems, 
Gels, Strips and compacts , Vesicular systems etc 
[10]. 
 
Fibers- 
Fibers, or thread-like devices, are reservoir-type 
systems, placed circumferentially into the pockets 
with an applicator and secured with cyanoacrylate 
adhesive for the sustained release of then trapped 
drug into the periodontal pocket... The release of the 
tetracycline from the cellulose acetate fibres as 
occurred by diffusion mechanism is rapid with 
approximately 95% of the drug released in the first 
two hours and, therefore, a single application of 
these fibres does not provide an effective drug 
concentration for long periods . Compared with the 
less effective tetracycline delivery from hollow 
fibres, fibres containing 20% (v/v) chlorhexidine, 
when placed into periodontal pockets, exhibited a 
prompt and marked reduction in signs and 
symptoms of periodontal disease. 
 
In spite of the fact that the hollow fibres served as a 
good drug holding device, they permitted rapid 
evacuation of the drug. To retard drug release, drug-
impregnated monolithic fibres were developed by 
adding drug to molten polymers, spinning at high 
temperature and subsequent cooling [11]. Several 
polymers such as poly(e-caprolactone) (PCL), 
polyurethane, polypropylene, cellulose acetate 
propionate and ethyl vinyl acetate (EVA) have been 
investigated as matrices for the delivery of drug to 
the periodontal pocket. In this respect, monolithic 
EVA fibres were found to be effective in controlling 
the release of encapsulated drug, and the same has 
been demonstrated by several in vitro and in vivo 
studies . Tonetti et al. reported that EVA fibres 
containing 25% tetracycline hydrochloride 
maintained a constant drug level in the GCF above 
600 mg/ml throughout ten days, showing zero-order 
release characteristics of EVA fibres . In addition to 
the extensive evaluation of drug delivery kinetics 
from the EVA fibres, this system has undergone 
numerous clinical trials to test its efficacy in the 
treatment of periodontal diseases. A study 
conducted on 121 sites in 20 patients evaluated the 
safety and efficacy of tetracyclineloaded EVA 
fibres applied after scaling and root planning (SRP) 
for ten days. The study indicated that a significant 
reduction in probing depth and gain in attachment 
was present at one-, threeand six-month visits. A 
reduction in proportion of bleeding pockets was 
observed during the experimental period. 
Tetracycline fibre treatment adjunctive to SRP 
showed significantly less periodontal disease 
recurrence (4%) compared with SRP alone (9%), 
tetracycline fibre alone for 10 days (10%) and 
tetracycline fibre alone for 20 days (12%). Studies 
that were wellconducted and well-controlled have 
demonstrated the clinical efficacy of these fibres but 
their actual value in patient therapy has been 
somewhat difficult to interpret because clinicians 
have found the fibre placement technique 
challenging. A study showed that patients 
experienced discomfort during fibre placement and 
at fibre removal various degrees of gingival redness 
were observed . The intricacies of winding a fibre 
into place, the need to retain the device within the 
pocket and then the removal of it after seven to ten 
days may limit its wide acceptance by patients and 
periodontists. Fibers are used for the treatment of 
periodontitis- Hollow fiber and monolithic. 
Hollow fibers comprise of reservoirs without rate 
controlled delivery filled with therapeutic agent. In 
these the therapeutic agent is released simply by 
diffusion through the reservoir wall. Goodson’s first 
delivery devices involved hollow fibers of cellulose 
acetate filled with tetracycline. Reduction in 
spirochete number and a reduction in clinical signs 
were produced by these fibers when placed into 
periodontal pocket. However the hollow fiber 
system released the drug very rapidly and was not 
very successful at sustaining the drug release. 
Monolithic fibers were essentially developed to 
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retard drug release. Monolithic fibers were made of 
ethylene vinyl acetate loaded with 25% tetracycline 
hydrochloride were placed to fill the periodontal 
pocket of 10 patients, which was covered with a 
periodontal dressing. The average concentration of 
tetracycline in pocket after 10 day was 643 μg/ml 
and the total count of pocket microflora was 
depressed to a level near the limit of dark field 
microscopy. In the cases presented tetracycline fiber 
were employed as a supplement to mechanical 
therapy and oral hygiene in a variety of clinical 
situation. Outcomes included depression of 
periodontal pathogens, reduction of bleeding on 
probing, decrease in probing pocket depths and 
increase in probing attachment levels [12]. 
 
Films  
A far more widely used form of intra-pocket 
delivery device has been in the shape of film, 
prepared either by solvent casting or direct milling. 
Bigger films either could be applied within the 
cavity onto the cheek mucosa or gingival surface or 
could be cut or punched into appropriate sizes so as 
to be inserted into the site of action. Films are 
matrix delivery systems in which drugs are 
distributed throughout the polymer and release 
occurs by drug diffusion and/or matrix dissolution 
or erosion. Films of various polymers have been 
made for the controlled release of therapeutic 
agents. Sustained release devices composed of 
cross-linked fish gelatin (bycoprotein) containing 
chlorhexidine diacetate or chlorhexidine 
hydrochloride have been developed by Steinberg. 
Films based on synthetic biodegradable polymers 
such as poly (lactide-co-glycolide) (PLGA) 
containing tetracycline have been developed for 
modulated-release of drug in the periodontal pocket 
as slab like device. In vitro release study showed 
that insoluble films release drug by diffusion and 
soluble release drug by dissolution of the carrier. 
The advantages of such a device include ease of 
insertion, dimensions that confirms well with the 
dimensions of the pocket and minimum pain on 
insertion. With the realization that pocket bacteria 
accumulate as biofilms, studies are now being 
directed towards eliminating /killing biofilms 
concentration rather then planktonic (fluid phase) 
counterparts. Intraperiodontal pocket drug delivery 
has emerged as a novel paradigm for the future 
research [13]. Some natural biodegradable polymers 
have been used for controlled release of 
antibacterial agents in the treatment of periodontitis. 
Sustained release devices composed of across-
linked fish gelatin (Byco protein) containing 
chlorhexidine diacetate or chlorhexidine 
hydrochloride have been developed by Steinberg et 
al. The in vitro release profile of chlorhexidine from 
such degradable films is dependent on the amount 
of chlorhexidine incorporated into the film, by the 
cross-link density of the polymer and by the 
chlorhexidine salt used. The time of total drug 
release is short and varies from 4 to 80 h. Among 
synthetic biodegradable polymers used as films for 
controlled release of antimicrobial agents, systems 
based on poly (ortho esters) have also been studied 
for the delivery of metronidazole. The in vitro study 
showed the influence of drug loading, film 
thickness and oleic acid content on drug release rate 
and profile. This dosage form has several 
advantageous physical properties for intra-pocket 
use. The dimensions and shape of the films can be 
easily controlled according to the dimensions of the 
pocket to be treated. It can be rapidly inserted into 
the base of the pocket with minimal discomfort to 
the patient. If the thickness of the film does not 
exceed 400 mm, and it has sufficient adhesiveness, 
it will remain submerged without any noticeable 
interference with the patient’s oral hygiene habits. 
Films that release drugs by diffusion alone are 
prepared using water-insoluble non-degradable 
polymers , whereas those that release by diffusion 
and matrix erosion or dissolution use soluble or 
biodegradable polymers [14]. Non-biodegradable 
ethyl cellulose based films for the delivery of 
chlorhexidine diacetate, metronidazole, tetracycline 
and minocycline have been developed by solvent 
evaporation method and clinically tested. Ethyl 
cellulose films showed sustained drug release and 
release rates were dependent on the casting solvent 
and drug load. The use of chloroform as the casting 
solvent significantly retarded the release rate of the 
drug compared to ethanol as the casting solvent. 
The incorporation of polyethylene glycol in the 
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films, however, enhanced the release rate of the 
drugs. Published clinical findings also confirmed 
that the treatment with drug-loaded ethyl cellulose 
films produced significantly greater improvements 
in the incidence of bleeding on probing, probing 
depths and attachment levels when compared to the 
conventional maintenance treatment. In contrast to 
the non-degradable systems discussed above, the 
films made up of degradable polymers erode or 
dissolve in the gingival crevice so that removal after 
treatment is not required. Natural and synthetic 
biopolymers play a pivotal part in drug delivery to 
periodontal pocket. Amongst natural biopolymers, 
atelocollagen, a pepsindigested preparation of 
insoluble bovine skin collagen, has been 
investigated as a possible carrier material for 
antibacterial agents in periodontal disease. 
Prolonged concentration of tetracycline in GCF 
could be maintained for at least ten days by 
incorporating the drug in glutaraldehyde cross-
linked atelocollagen. Application of these films 
resulted in a significant improvement in clinical 
parameters. Another natural polymer, gelatin 
(Byco1 protein), obtained from fish, was cross-
linked and used as a sustained release device for the 
delivery of chlorhexidine diacetate or chlorhexidine 
hydrochloride. In vitro drug release from such 
degradable films varied from 4 to 80 hours, 
depending on the amount of drug and cross-link 
density of the polymer. More recently, a film 
composed of cross-linked hydrolysed gelatin and 
glycerine for local delivery of chlorhexidine 
digluconate has been developed and 
commercialised under the tradename Periochip. The 
system showed an initial burst effect, whereby 40% 
of chlorhexidine was released in the first 24 hours, 
followed by a constant slower release over about 
seven days. This film has the advantage over other 
biodegradable films in which it remains inside the 
pocket with no additional aids for retention because 
of the adhesive nature of the Periochip1 
components . The novel natural polymer chitosan is 
also utilised as a polymeric matrix in the form of 
film enriched with taurine (antioxidant  agent). 
Taurine enhances the wound healing ability of 
chitosan and could be considered beneficial in 
tissue repair in destructive diseases like 
periodontitis. Furthermore, Perugini et al. carried 
the periodontal delivery of ipriflavone in a new 
chitosan/PLGA film delivery system. Monolayer 
films made of ipriflavone-loaded PLGA 
micromatrices in a chitosan film were compared 
with multilayer films composed of 
chitosan/PLGA/chitosan (three layers). In vitro 
experiments demonstrated that the composite 
micromatricial films represent a suitable dosage 
form to prolong ipriflavone release for 20 days. In 
another study, a two-layered film utilising 
mucoadhesive chitosan and biodegradable PCL was 
prepared. The film containing chitosan:PCL in the 
ratio of 1:0.625 had the best tensile properties and 
the slowest metronidazole release rate. In vivo 
evaluation of this film revealed that metronidazole 
concentration in saliva over six hours ranged  from 
5 to 15 mg/ml, which was within (and at the top end 
higher than) the reported range of minimum 
inhibitory concentration for metronidazole. A 
significant in vitro:in vivo correlation under the 
adopted experimental conditions was also obtained. 
The distinguishable films composed of poly(vinyl 
alcohol) (PVA) and carboxymethyl-chitosan 
(CMCS) were prepared by blending/ casting 
methods, and loaded with ornidazole as a 
periodontal drug delivery system. The blended films 
were found to be biocompatible, showed pH-
responsive swelling, had a good retention at the 
application site and maintained high drug 
concentration at least for five days. 
Synthetic biodegradable polymers have also been 
evaluated for sustained release of drug in the 
periodontal pocket. The combination of amoxycillin 
and metronidazole in the carrier polymer PLGA 
showed not only an extended spectrum of 
antimicrobial activity but also a synergistic effect 
against E. limosum, which had been reported to be 
resistant to metronidazole in earlier studies. The 
films showed a sustained in vitro release for a 
period of 16 days and the in vivo drug 
concentrations were maintained above the MIC 
value for the entire period of the release studies. By 
contrast, PLGA films containing tetracycline 
hydrochloride showed poor retention in the 
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periodontal pockets with incomplete release of 
tetracycline. This effect could be attributed to the 
hydrophobic nature of PLGA matrix and the 
difference in physicochemical properties of the 
drugs. Another biodegradable polymer poly(ortho 
esters) was also explored for the controlled delivery 
of metronidazole; however, no study on patients has 
been reported. Higashi et al. prepared films of 
water-soluble polymer Eudragit S1 and non-water-
soluble polymer Eudragit L1 for the delivery of 
clindamycin. An in vitro release study showed that 
insoluble films release drug by diffusion and 
soluble films release drug by dissolution of the 
carrier. Kyun and co-workers showed that by 
embedding minocycline in PCL it is feasible to 
obtain sustained release of the drug within the 
periodontal pocket for seven days and should be a 
useful tool for the elimination of pathogenic 
microflora from periodontal pocket or reducing 
inflammation in periodontal disease. Dedein et al. 
performed a clinico-laboratory study for the 
treatment of periodontal diseases using 
chlorhexidine-loaded Diplen-Denta films. The new 
treatment was found to be highly effective in 
patients with catarrhal gingivitis and generalised 
periodontitis of light and medium severity . 
 
Injectable System  
Injectable systems are particularly attractive for the 
delivery of antibiotic agents into the periodontal 
pocket. The application can be easily and rapidly 
carried out, without pain, by using a syringe. Thus, 
the cost of the therapy is considerably reduced 
compared to devices that need time to be placed and 
secured. Moreover, an injectable delivery system 
should be able to fill the pocket, thus reaching a 
large proportion of pathogens. These systems allow 
easy application of therapeutic agent using a 
syringe. They are also cost saving.  
 
Gels 
Mucoadhesive, MTZ containing gel systems based 
on hydroxyethyl cellulose, corbopol 974, and 
polycarbophil have been made. Gel is applied 
sublingually with the help of blunt cannula and 
syringe. The gel is only marginally affective in 
decreasing the anaerobic bacterial count. This may 
be due to low number of bacteria susceptible to 
MTZ or due to presence of bacterial biofilms. 
Locally applied controlled release DOX gel may 
partly counteract the negative effect of smoking on 
periodontal healing following no surgical therapy 
[15]. The first was tetracycline base loaded into the 
microtubular excepient halloysite, which was coated 
with chitosan to further retard drug release. The 
syringeability of this formulation at various 
temperatures was evaluated to ensure ease of 
delivery to periodontal pocket. A stability study was 
performed to examine change in thermoresponsivity 
over time [16]. In addition, lidocaine release from 
gels was evaluated using a release apparatus 
stimulating buccal condition .The results indicated 
that an increase in carbopol concentration 
significantly increased gel compressibility, hardness 
and adhesiveness factors that affect ease of gel 
removal from container, ease of gel application onto 
mucosal membrane, and gel bioadhesion . 
Characterization of tetracycline containing 
bioadhesive polymer network designed for the 
treatment of periodontal disease and result shows 
that effect of increasing drug concentrations on the 
rheological and textural properties was dependent 
on PVP concentration. Locally applied controlled 
release DOX gel may partly counteract the negative 
effect of smoking on periodontal healing.  The 
safety profile, longer-term retention, antimicrobial 
activity suggests that tetracycline containing 
copolymer gels represents a safe and effective 
bioerodible therapy for periodontitis. Growing 
interest in developing absorbable pharmaceutical 
surgical products that degrade in biologic 
environment to safe by products and leaves the 
residual mass at application site justified the search 
fir novel absorbable gels. Comparative analysis of 
tetracycline containing dental gels: poloxamer and 
monoglyceride based formulations have been done 
which shows that   poloxamer and monoglyceride 
gels, when applied subgingivally, produce a 
significant improved outcome in moderate to deep 
periodontal pockets [17]. 
 
Injectable Gels 
Together with the solid devices, semisolid 
formulations also receive reasonable attention for 
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the localised delivery of antibiotics. Semisolid or 
gel formulations can indeed have some advantages. 
In spite of the relatively faster release of the 
incorporated drug, gels can be more easily prepared 
and administered. Moreover, they possess a higher 
biocompatibility and bioadhesivity, allowing 
adhesion to the mucosa in the dental pocket and, 
finally, they can be rapidly eliminated through 
normal catabolic pathways, decreasing the risk of 
irritative or allergic host reactions at the application 
site. Various oleogels and hydrogels for the delivery 
of tetracycline (2.5%), metronidazole (25%), 
metronidazole benzoate (40%), as well as a 
combination of tetracycline (2.5%) and 
metronidazole benzoate (40%), have been tested 
and satisfactory results have been achieved. The 
gels composed of cellulose derivatives such as 
hydroxypropylmethyl cellulose and hydroxyethyl 
cellulose do not appear to have sustained release 
properties. Surprisingly, despite the rapid drug 
release and poor retention of these gels, positive 
clinical results in moderate to deep periodontitis 
were obtained. Bioadhesion or mucoadhesion is a 
preliminary requirement for prolonged release of 
the drug at the site [18]. The retention time, as 
determined by fluorescein release, was found to be 
significantly higher for chitosan gel as compared to 
xanthan gum and poly(- ethylene oxide) gel. 
Chitosan, a novel biodegradable natural polymer, in 
a gel form (1%, w/w) with or without 15% 
metronidazole, had demonstrated effectiveness in 
the treatment of chronic periodontitis. Bioadhesive 
semisolid, polymeric system can be utilised as an 
important intra-pocket delivery vehicle because it 
can easily pass through a cannula into a periodontal 
pocket where it solidifies in situ to deliver the 
therapeutic agent for a prolonged period. These 
systems exhibit a pseudoplastic flow and 
thermoresponsive behaviour, existing as a liquid at 
room temperature and gel at 34–37 8C. 
Tetracycline-loaded bioadhesive semisolid, 
polymeric system based upon hydroxyethyl 
cellulose- and polyvinylpyrrolidone- and 
metronidazole-loaded systems based upon Carbopol 
974P, hydroxyethyl cellulose and polycarbophil are 
reported. Another such system composed of 
Poloxamer 407 and Carbopol 934P and containing 
propolis extract were designed for the treatment of 
periodontal disease. The release of the propolis was 
controlled by the relaxation of polymer chains and 
the greatest mucoadhesion was noted for the 
formulation containing 60:1 ratio of Poloxamer 
407:Carbopol 934P. Another injectable 
biodegradable gel based on poly(DL-lactide) 
dissolved in a biocompatible solvent N-methyl-2-
pyrrolidone (NMP) (Atrigel1) was widely studied . 
The Atrigel1 loaded with 10% doxycycline hyclate 
showed high levels of doxycycline (250 mg/ml) in 
the GCF for a period of seven days. Interestingly, 
levels of 10–20 mg/ml were still present for three to 
five days after the polymer had been removed. It is 
possibly because of minute particles of polymer 
remaining within the pockets or because of the 
substantive effects of tetracyclines within the 
periodontal pocket-adjacent-tooth-surface 
environment. In another study, Atrigel1 containing 
5% sanguinarine was found to be superior to the 
control in the treatment of adult periodontitis and 
the findings have been recently confirmed in a 
human clinical trial. The semisolid system based on 
water-free mixtures of lipids, such as glycerol 
monooleate (monoglyceride) and sesame oil 
(triglyceride), is characterised by a solid–gel 
transition and become semisolid on contact with 
gingival fluid in the periodontal pocket. The system 
is based on the ability of glycerides to form liquid 
crystals, that is, reverse hexagonals on contact with 
water. The reverse hexagonal form has more 
favourable sustained release properties, compared 
with the initial cubic form. The matrix is degraded 
by neutrophils and bacterial lipase in the GCF . 
Biodegradable gels are other useful prospects for 
the delivery of therapeutic agents into periodontal 
pockets. Bioerodible lactic– glycolic acid gels were 
found to be safe and tetracycline levels observed at 
days 3 and 8 probably represent significant 
antimicrobial efficacy. 
 
Strips and Compacts 
Acrylic strips have been fabricated using a mixture 
of polymers, monomers and different concentrations 
of ant microbial agents. Strips were fabricated either 
by solvent casting or pressure melt method. Strips 
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containing tetracycline, MTZ or chlorhexidine 
demonstrated a decrease in number of motile rods, 
notably spirochetes. In a later development, the 
evaluation of amoxycillin-clavulainic acid loaded 
acrylic strips is reported. Highest level of 
antibacterial agent was released during the first 24 
hours period followed by release of therapeutic 
level of drugs for a subsequent 9 days period. Effect 
persisted even after 3 week of removal of acrylic 
strips. Tissue adhesive implants were made using n-
butyl-2-cyanoacrylate as a drug trapping material 
and slowly release drug when used in the structure 
of a biodegradable local drug delivery device[19]. 
Ornidazole dental implants containing ethyl 
cellulose, hydroxy propyl cellulose, hydroxy propyl 
methyl cellulose, eudragit-RL-100 and di butyl 
phthalate by solvent casting technique result 
showed that drug release was initially high on day 
one to achieve immediate therapeutic level of drug 
in pocket, followed by marked fall in release by day 
two [20]. Chlorhexidine slow release devise has 
been made and it is antibacterial effect has been 
evaluated by agar diffusion test. 
 
 
 
 
Vesicular Systems 
Vesicular liposomal systems are designed to mimic 
the bio-membranes in terms of structure and bio-
behaviour, and hence are investigated intensively 
for targeting periodontal biofilms. Jones and 
Kaszuba reported interactions between liposomes 
made up of phosphatidylinositol (PI) and bacterial 
biofilms. The targeting of liposomes was thought to 
be because of the interaction of the polyhydroxy 
groups of liposomes with surface polymers of the 
bacterial glycol-calyx. Succinylated Concanavalin-
A (lectin)-bearing liposomes (proteoliposomes) 
have been found to be effective for the delivery of 
triclosan to periodontal biofilms. In vitro and in 
vivo studies have revealed that, even after a very 
short exposure, the proteoliposomes are retained by 
the bacteria eventually delivering triclosan into the 
cellular interiors. The potential of lectin-bearing 
liposome systems as a targeting system for the 
control of gingivitis and dental plaque has been 
extensively studied by Vyas et al [21]. The delivery 
of triclosan and chlorhexidine was studied for 
several liposomal compositions involving cationic 
as well as anionic lipids [22]. Robinson and co-
workers reported further on the affinity and 
specificity of immunoliposomes to reduce dental 
plaque. The anti-oralis immunoliposomes showed 
the greatest affinity for S. oralis and affinity was 
unaffected by net charge on the lipid bilayer or by 
the number of antibodies conjugated to the 
liposomal surface . 
 
Microparticle System   
Microparticles based system of biodegradable poly 
alpha hydroxy acids such as poly lactide (PLA) or 
poly (lactide – co-glycolide) PLGA containing 
tetracycline has been designed for periodontal 
disease therapy. PLGA microspheres containing 
minocycline have been formulated and have been 
used for the elimination of Porphyromonas 
gingivalis from the periodontal pocket . 
Microparticles of poly (dl-lactic-co-glycolic acid) 
(PLGA) containing chlorhexidine free base, 
chlorhexidine di gluconate and their association or 
inclusion complex with methylated-beta-
cyclodextrin (HPBCD) were prepared with single 
emulsion, solvent evaporation technique [23]. Non-
biodegradable as well as biodegradable materials 
have beeninvestigated for the preparation of 
microspheres. These materials include the polymers 
of natural origin, modified natural substances and 
synthetic polymers. They could preferably be 
formulated as a chip or could be part of a dental 
paste formulation, or otherwise be directly injected 
into the periodontal cavity. Tetracycline-
containingmicrocapsules in Pluronic F127were 
reported to formgel at body temperature and hold 
the microcapsules in the periodontal pocket for the 
duration of treatment. PLGAmicrocapsules and 
microspheres have been proposed for the delivery 
of tetracycline and histatins. These microparticulate 
systems provide stability to the encapsulated drug. 
The in vitro drug release from such systems 
depends upon the polymer (lactide:glycolide) ratio, 
molecular weight, crystallinity and pH of the 
medium. Some questions, however, related to the 
retention of such formulations in the periodontal 
pocket need clarification. Recently, the controlled 
delivery of doxycycline for up to 11 days was 
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achieved through novel biodegradablemicrospheres 
prepared by w/o/w double emulsion technique using 
the  Theformulationwas also effective in vivo 
andsignificant resultswere obtained with respect to 
microbiological and clinical parameters for up to 
three months . 
 
Nanoparticulate System 
Modern drug delivery systems are designed for 
targeted controlled slow drug release. Up to now 
polymer or microparticle-based hydrogels have 
been applied in dentistry, which can affect the rate 
of release because of their structure. Recently, 
intensive research is being performed all over the 
world to improve the effectiveness of delivery 
systems. The nanoparticulate system provides 
several advantages as compared with microspheres, 
microparticles and emulsion-based delivery 
systems, including high dispersibility in an aqueous 
medium, controlled release rate and increased 
stability. Nanoparticles, owing to their small size, 
penetrate regions that may be inaccessible to other 
delivery systems, such as the periodontal pocket 
areas below the gum line [11]. These systems 
reduce the frequency of administration and further 
provide a uniform distribution of the active agent 
over an extended period of time. Biocompatible 
nanoparticles composed of 2-hydroxyethyl 
methacrylate (HEMA) and polyethyleneglycol 
dimethacrylate (PEGDMA) could be used as a drug 
delivery system for dental applications. The 
polymer-based nanoparticles were prepared via 
micellar polymerisation, which resulted in a well 
dispersible white powder material with particle size 
in the range of 50–180 nm. These nanoparticles are 
suitable for incorporation into a hydrogel matrix 
and to design new drug delivery devices for dental 
applications. Moulari et al. investigated the in vitro 
bactericidal activity of the Harungana 
madagascariensis leaf extract (HLE) on the oral 
bacterial strains largely implicated in dental caries 
and gingivitis infections. HLE-loaded PLGA 
nanoparticles were prepared using interfacial 
polymer deposition following the solvent diffusion 
method. Incorporation of the HLE into a colloidal 
carrier improved its antibacterial performance and 
diminution of the bactericidal concentration was 
observed. Shefer and Shefer patented a controlled 
release system useful for site-specific delivery of 
biologically active ingredients over an extended 
period of time. This system is a multi-component 
release system comprising biodegradable 
nanoparticles having bioadhesive properties 
encapsulated within a moisture sensitive 
microparticle. The bioadhesive properties of the 
nanoparticles are attributed to the positively charged 
surfactant entrapped on the particle surface. The 
multi-component release system can be 
incorporated into any suitable oral hygiene product 
including gels, chewing gums, toothpaste and 
mouthwash for the treatment and prevention of 
periodontal disease. Antisense oligonucleotide- 
loaded chitosan-tripolyphosphate (TPP) 
nanoparticles were prepared and evaluated. 
Chitosan/oligonucleotide-TPP nanoparticles, which 
were prepared by adding TPP after the formation of 
chitosan/oligonucleotide complex, showed the 
sustained release of oligonucleotides and are 
suitable for the local therapeutic application in 
periodontal diseases [24]. In an attempt to obtain a 
novel delivery system adequate for the treatment of 
periodontal disease, triclosan-loaded polymeric 
(PLGA, PLA and cellulose acetate phthalate) 
nanoparticles were prepared by emulsification–
diffusion process. A preliminary in vivo study in 
dogs with induced periodontal defects suggested 
that triclosan-loaded nanoparticles penetrate 
through the junctional epithelium [25]. With the 
emergence and increase of microbial resistance to 
multiple antibiotics, the antibiotic-free delivery 
systems for periodontal infections have been tried. 
The problem of antibiotic resistance has led to 
resurgence in the use of Ag-based antiseptics that 
may be linked to broad-spectrum activity and far 
lower propensity to induce microbial resistance than 
antibiotics. Ag nanoparticles can be used as 
effective growth inhibitors in various 
microorganisms, making them applicable to treat 
periodontal diseases. Another approach is 
antimicrobial enzymes covalently attached to 
nanoparticles to generate antibiotic-free treatment 
for microbial infections. Satishkumar et al. 
developed a system in which hen-egg lysozyme 
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(antimicrobial enzyme) was covalently attached to 
two types of polystyrene latex nanoparticles: 
positively charged, containing aliphatic amines 
surface group; and negatively charged, containing 
sulphate and chloromethyl surface group. These 
particles were showing lower activity compared to 
free enzyme, but can be explored for targeted 
antimicrobial activity. 
 
Miscellaneous: low-dose antibiotic 
Recently, there has been interest in the use of low-
dose antibiotics. The dose is so low that the drug 
does not act to kill bacteria, but rather to change the 
way the body responds to infection. Production of 
the enzyme collagenase is essential because older 
gingival tissues are replaced with new tissues. In 
periodontal disease there is an overproduction of 
collagenase, causing the destruction of healthy gum 
tissue. An interesting effect of low-dose antibiotics 
is that they not only kill the bacteria that may cause 
periodontal disease but also reduce the body’s 
production of collagenase, an enzyme that destroys 
gingival tissues. The antibiotic doxycycline was 
found to combat these enzymes, even in doses so 
small that there was no antibiotic effect . The 
advantages of smaller doses are that there is a great 
reduction in the chances of formation of resistant 
bacterial strains and side effects. Periostat is a 
capsule of 20 mg of doxycycline, and clinical 
studies have shown that patients who take two 
capsules daily have a reduction in clinical 
inflammation . The daily 40-mg dose is so low as 
not to qualify as an antibiotic, and there is no 
known effect on the pocket bacteria. Thus, Periostat 
must be used in conjunction with other therapies 
that address bacterial removal [11]. 
Surgical treatment for periodontal diseases: 
Bone\Tissue grafts: - It is the method employed 
mostly to replace or speed up the formation of new 
cells of bone or gingiva, which is destroyed in 
periodontitis. The grafting also helps to prevent the 
gum tissue from growing into the area of the bone, 
allowing the gum and the bone to grow again. This 
technique is known as Guided Tissue Regeneration 
(GTR) [26].  
Flap Surgery: - This is next step of tissue grafting  
and is used when the periodontal pockets are still 
seen even after the use of medications and tooth-
cleaning techniques. This involves removal of the 
calculus and lifting back the gums. The gums are 
sutured back in place so that the tissue can re-grow 
and fit around the tooth. The success rate is very 
low in this type of surgery, because the gums have 
lost the stiffness and very rarely gain it again [26].  
Periodontal Maintenance Procedures 
Periodic monitoring of periodontal status and 
appropriate maintenance procedures should be part 
of the long-term treatment plan for managing 
chronic periodontitis. Although experimental 
studies have demonstrated very successful treatment 
outcomes when patients are professionally 
maintained at 2-week intervals, such a program is 
impractical for most chronic periodontitis patients. 
Therefore, to maximize successful therapeutic 
outcomes, patients must maintain effective daily 
plaque control. It also appears that in-office 
periodontal maintenance at 3 to 4 month intervals 
can be effective in maintaining most patients.  
 
 
 
 
Table 1-List of commercial periodontal products presented 
in various dosage forms [27] 
 
 
Product Antimicrobial Agent Dosage form Manufacturer 
Actinide® Tetracycline Non resorbable fiber Alzacorp
Arestin® Minocycline Bio degradable powder in syringe
Oropharma corp 
Warminster
Atridox® Doxycycline Biodegrable mix in syringe 
Atrix labs, Ft, 
Collins, co.
Dentamycin
e ®/ Minocycline 
Biodegrable mix 
in syringe 
Sunstar corp., 
Tokyo, Japan
Elyzol® Metronidazole Biodegrable mixture in syringe
Dumex corp. Co 
Denmark.
Periochip® Chlorhexidine Biodegradable device 
Dexcel Pharma 
Inc, Jerusalem, 
Periochip® Chlorhexidine /tetracycline Films Perioproducts Ltd. 
Periochip® Perioproducts Ltd. Insert Gluconate 
Gluconate® Perioproducts Ltd Insert Metronidazole 
Elyzol® Dumex pharma Gel Minocycline 
Atrigel ® Atridox (atrix Lab) Gel Doxycycline 
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Current status of intra-pocket delivery devices in 
periodontics 
 
 
 
 
With the current availability of number of intra-
pocket delivery systems containing antimicrobials 
for periodontal therapy, questions can be raised 
about the role of intra-pocket delivery devices in 
periodontics. Firstly, if intra-pocket delivery 
systems can deliver equivalent clinical results to 
SRP, should the use of these therapies be 
considered in place of SRP? Better still, how will 
antimicrobials be incorporated into treatment 
strategies with or without mechanical intervention? 
Lastly, to be considered are the physical properties 
of delivery system, which may influence the 
acceptance by the patient and professional 
community. Most reports on the local delivery 
concepts have appeared in the periodontal literature 
but there are surprisingly few studies that 
demonstrate the clinical efficacy using intra-pocket 
delivery systems in periodontitis patients. Despite 
the large number of studies, there are insufficient 
comparative data to support any one of the local 
delivery systems as superior to another because 
their treatment patterns differ widely. Great 
variability from site to site has been repeatedly 
noted by investigators showing that the same 
system could not work equally in all sites and in all 
patients. Many studies have failed to show real and 
clinically meaningful effects provided by the intra-
pocket drug delivery systems when used as stand-
alone monotherapies. Other studies have 
demonstrated that these systems have beneficial 
effects in terms of probing depth reduction; 
however, the statistical significance reached in these 
studies was not always clinically significant. 
 
The strategic approaches with associated 
challenges and achievements towards the 
formation of periodontal drug delivery system 
[29-32] 
Challenges Goals achieved 
Strategy 1: systemic delivery devices 
• Low benefit to risk ratio, ingestion of large 
drug doses 
• Inadequate drug concentration at periodontal 
site 
• Rapid/non-sustained drug release 
• Poor patient compliance: frequent 
administration 
• No penetration of delivery system 
• No adhesion/retention into periodontal 
pocket 
• High incidence of bacterial resistance 
Strategy 2: local mouth rinses and dental irrigation 
• Inadequate drug concentration at periodontal 
site Drug dose is reduced 
• Rapid/non-sustained drug release Systemic 
toxicity is decreased 
• Poor patient compliance: frequent 
administration 
• No penetration of delivery system 
• No adhesion/retention into periodontal 
pocket 
• High incidence of bacterial resistance 
Strategy 3: non-biodegradable, intrapocket fibres, 
strips, films and microparticles 
• Poor patient compliance: discomfort during 
the placement 
• of device, at least two visits to therapist is 
required and development of foreign body 
response, if left in situ Adequate drug 
concentration at periodontal site 
• Poor penetration of system/drug 
Prolonged/sustain drug release 
• Poor retention of system into periodontal 
pocket Less frequent administration 
• Low incidence of bacterial resistance 
Strategy 4: biodegradable, intra-pocket fibres, 
strips, films and microparticles 
• Poor patient compliance: discomfort during 
placement Visit to therapist is reduced 
• Poor penetration of system/drug No foreign 
body response 
• Poor retention of system into periodontal 
pocket 
• Low incidence of bacterial resistance 
Strategy 5: biodegradable nanoparticles 
• Poor retention of system into periodontal 
pocket Placement is easier 
• Low incidence of bacterial resistance Good 
penetration due to nano-sized particles 
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Strategy 6: Mucoadhesive, biodegradable 
nanoparticles 
• Low incidence of bacterial resistance Good 
retention of system 
Strategy 7: antibiotic-free, mucoadhesive, 
biodegradable nanoparticles 
• Bacterial resistance does not develop 
 
Conclusion 
From the preceding review of the recent advances in 
periodontal drug delivery systems it can be said that 
the antibiotic-free, mucoadhesive, biodegradable 
nanoparticles technology has an immense 
opportunity for the designing of a novel, low-dose 
and effective treatment method by the use of the 
intra-pocket controlled device..These devices are 
proving to be more convenient, easy-to-use and 
more effective than the regular drugs and medicines 
which act systemically. These devices also do not 
probe the risk of overdose or systemic overload, 
simple for formulation, affordable and easily 
available 
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